论文部分内容阅读
目的探讨激肽释放酶14(kallikreinl4)在卵巢癌组织的表达及临床意义。方法应用SP和ELISA法检测不同卵巢患者KLK14蛋白的表达和KLK14血清学的浓度。结果卵巢癌组KLK14蛋白表达阳性率/血清学浓度明显高于卵巢良性上皮肿瘤组和正常卵巢组。KLKl4蛋白表达与卵巢癌患者的临床分期,组织学分级有关。结论 KLKl4过表达与卵巢癌的发生、侵袭相关,提示其可能成为卵巢癌的标志物。
Objective To investigate the expression of kallikrein 14 in ovarian cancer and its clinical significance. Methods The expression of KLK14 protein and the concentration of KLK14 in different ovarian tissues were detected by SP and ELISA. Results The positive rate of KLK14 protein in ovarian cancer group was significantly higher than that in benign epithelial ovarian tumor group and normal ovary group. KLKl4 protein expression and ovarian cancer clinical stage, histological grade related. Conclusion The overexpression of KLKl4 is associated with the occurrence and invasion of ovarian cancer, suggesting that it may become a marker of ovarian cancer.